Compare ARK Fintech Innovation ETF (ARKF) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Fintech Innovation ETF vs Gilead Sciences, Inc. — how do they compare? ARK Fintech Innovation ETF trades at $43, while Gilead Sciences, Inc. trades at $135 (market cap $164.99B). The key difference: Gilead Sciences, Inc. pays a 2.47% dividend while ARK Fintech Innovation ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, ARK Fintech Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKF | GILD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $58.82 | $155.80 |
52-Week Low | $36.14 | $110.56 |
Market Cap | — | $164.99B |
Enterprise Value | — | $188.06B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKF trades at $42.54, up 1.48% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has underperformed the S&P 500, down 23% since July 2025, and faces elevated volatility. Recent news highlights its fintech and crypto exposure amid market consolidation, with a Hold rating due to fair valuation concerns.
Outlook remains cautious; high P/E of 33x and PEG of 2.0x suggest overvaluation risks, while sector consolidation offers potential recovery if market sentiment improves. Key risks include sustained underperformance and portfolio volatility, requiring careful monitoring of fintech sector trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Fintech Innovation ETF
ARKF is an actively managed ETF that invests in companies leading the way in fintech innovation. Key themes include mobile payments, digital wallets, blockchain technology, and frictionless funding platforms.
Read more on ARKF →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
